Plasmodium hypnozoite stage

The Plasmodium hypnozoite stage is the dormant developmental form of malaria parasites (notably Plasmodium vivax and Plasmodium ovale) that persists in the hepatocytes (liver cells) of infected humans. Hypnozoites can remain quiescent for weeks to years before reactivating, leading to relapse with secondary blood-stage malaria. This stage is asymptomatic and undetectable by standard diagnostics, posing a major hurdle to malaria eradication. Therapeutic strategies targeting hypnozoites—such as 8-aminoquinoline drugs (primaquine, tafenoquine) and experimental compounds (hydralazine, cadralazine, AQP3 inhibitors)—aim to achieve radical cure by killing these dormant forms and preventing relapses. However, development of safer, broadly effective hypnozoitocidal agents remains a critical and unmet need due to host toxicity, lack of culture models, and incomplete knowledge of hypnozoite biology.

Other names

hypnozoitePlasmodium dormant liver stagedormant hepatic stage

Cellular death of dormant parasite (direct or via unknown mechanisms). Targeting metabolism or unique biology of dormant hypnozoite (e.g., DNA methylation disruption, unknown parasite or host interactions like AQP3). AQP3 inhibition (for some non-8-aminoquinoline compounds).